1. Abosede OA. Self-medication: an important aspect of primary health care. Soc. Sci. Med. 1984; 19: 699-703.

2. Adam C, Cavendish W, Mistry PS. Adjusting privatization: case studies from developing countries. London: James Currey; 1992.

3. Andajaningsih. Quality, safety and efficacy (QSE) of medicines. Indonesia country report. Sydney: International Conference on National Medicinal Drug Policies; 1995.

4. Anderson L, Higby G J. The spirit of voluntarism. The United States Pharmacopeia, 1820-1995. Rockville, USA: The United States Pharmacopeial Convention, Inc. (USPC); 1995.

5. Antezana F, Velasquez G. Drugs and health sector reform. WHO Task Force on Health Economics. Geneva: World Health Organization; 1996. WHO/TFHE/96.2.

6. Arrow KJ. Uncertainty and the welfare economics of medical care. American Economic Review. 1963; 53(5): 941-973.

7. Asiimwe D, McPake B, Mwesigye F, Streefland P. The private behaviour of public health workers: the case of Uganda. In: Private health care providers in developing countries: serving the public interest? Bennett S, McPake B, Mills A. London: Zed Press; 1997.

8. Balasubramaniam K. Strategies to ensure availability & affordability of safe and effective drugs of good quality in the Asia-Pacific Region. Conference presentation. Sydney: International Conference on National Medicinal Drug Policies; 1995.

9. Ballance R, Pogány J, Forstner H. The world's pharmaceutical industries. An international perspective on innovation, competition and policy. Prepared for United Nations Industrial Development Organization. Aldershot: Edward Elgar Publishing Limited; 1992.

10. Bartholet J. The case of the killer aspirin. Newsweek; 1990.

11. Bennett S, Dakpallah G, Garner P, Gilson L, Nittayaramphong S, Zurita B. Carrot and stick: state mechanisms to influence private provider behaviour. Health Policy Plan. 1994; 9 (1): 1-13.

12. Bennett S. The mystique of markets: public and private health care in developing countries. London: London School of Hygiene & Tropical Medicine; 1991. PHP Departmental Publication, N° 4.

13. Bennett S, Ngalande-Banda E. Public and private roles in health: a review and analysis of experience in sub-Saharan Africa. Geneva: World Health Organization; 1994.

14. Berman P, Hanson K. Assessing the private sector: using non-government resources to strengthen public health goals. Data for decision-making project. Boston, MA: Harvard University; 1994.

15. Berman P, Nwuke K, Hanson K, Kariuki M, Mbugua K, Ngugi J, et al. Kenya: non-governmental health care provision. Boston: DDM project, Harvard School of Public Health; 1995.

16. Berman P, Nwuke K, Rannan-Eliya R, Mwanza A. Zambia: non-governmental health care provision. Boston: DDM Project, Harvard School of Public Health; 1995.

17. Bevan G. Equity in the use of health care resources. Current concerns. SHS paper N°3. Geneva: World Health Organization; 1991. WHO/SHS/CC/91.1.

18. Bidwai P. One step forward, many steps back: dismemberment of India's National Drug Policy. Dev Dialogue. 1995; 1: 193-222.

19. Biersteker T, Adenika F, Brown GC. Study of potential for private sector participation in drug supply. Geneva: World Health Organization; 1987.

20. Blakney RB, Litvack JI, Quick JD. Financing primary health care: experiences of pharmaceutical cost recovery. Arlington, VA: PRITECH Project; 1989.

21. Bloom G, Lucas H, Cao S, Gao J, Yao J, Xing-yan G. Financing health services in poor rural areas: adapting to economic and institutional reform in China. Brighton: Institute for Development Studies; 1995.

22. Braveman P. Equity in health and health care: a WHO/SIDA initiative. Geneva: World Health Organization; 1996.

23. Brudon-Jakobowicz P, Rainhorn J, Reich MR. Indicators for monitoring national drug policies. Geneva: World Health Organization; 1994. WHO/DAP/94.12.

24. Bryant JH. Equity, solidarity and sustainability - critical underpinnings for the future Health-For-All strategy. Interregional meeting on Health-For-All renewal, Geneva, 26-30 August 1996. Unpublished.

25. Carrin G, Ron A, Wang SC, Xuesheng L, Jun Y, Hui Y, et al. The reform of the rural cooperative medical system in the People's Republic of China: initial design and interim experience. Geneva: World Health Organization; 1996.

26. Cassels A. Health sector reform: key issues in less developed countries. Discussion paper N° 1. Geneva: World Health Organization; 1995. WHO/SHS/NHP/95.7.

27. Cederlof C. Health and profits - can they ever meet? Using private pharmacies to look at pharmacoeconomics. Stockholm: Karolinska Institutet; 1993. IHCAR Report 2/93-94.

28. Collective work, Disponibilité des médicaments essentiels. In: Le secteur pharmaceutique privé commercial en Afrique. Kaddar M, Bruneton C. Paris: Ministère de la Coopération - Organisation mondiale de la Santé; 1996: 60-61.

29. Correa CM. The Uruguay round and drugs. WHO Task Force on Health Economics. Geneva: World Health Organization; 1995. WHO/TFHE/97.1.

30. Creese A L. User charges for health care: a review of recent experience. London: Oxford University Press; 1991.

31. Creese A L. Review article: User charges for health care: a review of recent experience. Health Policy Plan. 1991; 6 (4): 309-319.

32. Creese A L, Kutzin J. Lessons from cost-recovery in health. Forum on health sector reform. Discussion paper N° 2. Geneva: World Health Organization; 1995.

33. Csete J. Health-seeking behavior of Rwandan women. Soc. Sci. Med. 1993; 37: 1285-1292.

34. Culyer AJ, Maynard A, Posnett J. Reforming health care: an introduction to the economic issues. In: Competition in health care: reforming the NHS. Culyer AJ, Maynard A, Posnett J. Basingstoke: Macmillan Press; 1990: 1-11.

35. Diarra K, Coulibaly S. Financing of recurrent health costs in Mali. Health Policy. 1990; 5(2): 126-138.

36. Donaldson D. Privatization: principles and practice. Washington, D C: International Finance Corporation; 1995.

37. Dua V, Kunin C M, Vanarsdale White L. The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Soc. Sci. Med. 1994; 38: 717-724.

38. Dukes MNG, Change and growth in generic markets in developed and developing countries. In: Seminar on medicines and the new economic environment (Madrid, 29-31 March 1995) organized by WHO Action Programme on Essential Drugs and the Universidad Carlos III de Madrid. Madrid: Universidad Carlos III de Madrid; 1995: 1-19.

39. Ettling M, McFarland DA, Schultz LJ, Chitsulo L. Economic impact of malaria in Malawian households. Trop. Med. Parasitol. 1994; 45: 74-79.

40. Fefer E. Future challenges in regulatory control. Unpublished.

41. Galvez Tan J. The Philippines national drug policy programme. Conference presentation, 8-11 October 1995. Sydney: International Conference on National Medicinal Drug Policies; 1995.

42. GAO. Prescription drugs: companies typically charge more in the United States than in the United Kingdom. Report to the Chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives. GAO/HEHS-94-29. Washington, D C: General Accounting Office; 1994.

43. GAO. Prescription drugs: spending controls in four European countries. Report to the Chairman, Special Committee on Aging, U.S. Senate. GAO/HEHS-94-30. Washington, D C: General Accounting Office; 1994.

44. Gilson L, Dave Sen P, Mohammed S, Mujinja P. The potential of health sector non-governmental organizations: policy options. Health Policy Plan. 1994; 9 (1): 14-24.

45. Gilson L. Government health care charges: is equity being abandoned? Evaluation and Planning Centre discussion paper, N° 15. London: University of London School of Hygiene & Tropical Medicine; 1988.

46. Gothoskar SS. Drug control: India. World Development. 1983; 11(3): 223-228.

47. Grabowski H, Mullins D. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc. Sci. Med. 1997; 4: 535-544.

48. Greenhalgh T. Drug prescription and self-medication in India: an exploratory survey. Soc. Sci. Med. 1987; 25: 307-318.

49. Griffin CC. Strengthening health services in developing countries through the private sector. Washington, D C: World Bank; 1989. IFC discussion paper N°4.

50. Grupper M. Drug cost containment policies: a new challenge for the future. Unpublished.

51. Haaijer-Ruskamp FM, Dukes MNG. Drugs and money. The problem of cost containment. 6th edition. Groningen: WHO Collaborating Centre for Clinical Pharmacology and Drug Policy Science and Pharmaceuticals Unit, World Health Organization, Regional Office for Europe. STYX Publications; 1991.

52. Haak H, Hardon AP. Indigenised pharmaceuticals in developing countries: widely used, widely neglected. Lancet. 1988; 2: 620-621.

53. Hardon A, van der Geest S. Hazards of self-medication. World Health Forum. 1987; 8: 469-471.

54. Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J. Clin. Pharmac. 1995; 39: 1-6.

55. Igun UA. Why we seek treatment here: retail pharmacy and clinical practice in Maiduguri, Nigeria. Soc. Sci. Med. 1987; 24: 689-695.

56. ITC. Pharmaceutical raw materials/essential drugs report. Market News Service. Geneva: International Trade Centre UNCTAD/GATT; 1995.

57. Jayasuriya DC. Regulation of pharmaceutical in developing countries: legal issues and approaches. Geneva: World Health Organization; 1985.

58. Kafle KK, Gartoulla RP, Pradhan YM, Shrestha AD, Karkee SB, Quick JD. Drug retailer training: experiences from Nepal. Soc. Sci. Med. 1992; 35(8): 1015-1025.

59. Kamat VR, Nichter M. Monitoring product movement: an ethnographic study of pharmaceutical sales representatives in Bombay, India. In: Private health providers in developing countries: serving the public interest? Bennett S, McPake B, Mills A. London: Zed Press; 1997:

60. Kapil I. Doctors dispensing medications: contemporary India and 19th century England. Soc. Sci. Med. 1988; 26: 691-699.

61. Katz J, (2.1) The drug industry of Argentina, Brazil, and Mexico after trade liberalization and market de-regulation. In: Report of an informal consultation on evolving public-private roles in the pharmaceutical sector. Geneva: World Health Organization; 1997: WHO/DAP/97.10.

62. Kinnon CM. WTO: what's in it for WHO? Geneva: World Health Organization; 1995. WHO/TFHE//95.5.

63. Kunin CM. Use of antimicrobial drugs in developing countries. International Journal of Antimicrobial Agents. 1995; 5: 107-113.

64. Kutzin J. Experience with organizational and financing reform of the health sector. Current Concerns SHS Paper, N°. 8. Geneva: World Health Organization; 1994. WHO/SHS/CC/94.3.

65. Kutzin J, Barnum H. How health insurance affects the delivery of health care in developing countries. Washington, D C: World Bank; 1992: 1-20.

66. Lansang MA, Lucas Aquino R, Tupasi TE, Mina VS, Salazar LS, Juban N, et al. Purchase of antibiotics without prescription in Manila, the Philippines. Inappropriate choices and doses. J Clin Epidemiol. 1990; 43: 61-67.

67. Liu Y, Hsiao WCL, Li Q, Liu X, Ren M. Transformation of China's rural health care financing. Soc. Sci. Med. 1995; 41(8): 1085-1093.

68. McPake B, Hanson K, Mills A. Community financing of health care in Africa: an evaluation of the Bamako initiative. Soc. Sci. Med. 1993; 36 (11): 1383-1395.

69. McPake B, Ngalande-Bande E. Contracting out health services in developing countries. Health Policy Plan. 1994; 9 (1): 25-30.

70. MEDS. Report of the MEDS operations & proposal for 36 months extension of funding. Nairobi: Mission for Essential Drugs and Supplies, Kenya; 1990.

71. MEDS. Report of an annual conference. Nairobi: Mission for Essential Drugs and Supplies, Kenya; 1993.

72. Mills A, Chapter 4. Economic aspects of health insurance. In: The economics of health in developing countries. Lee K, Mills A. Oxford: Oxford University Press; 1985: 65-87.

73. Mills A. The household costs of malaria in Nepal. Trop. Med. Parasitol. 1993; 44: 9-13.

74. Mills A, Contractual relationships between government and the commercial private sector in developing countries: are they a good idea in health? In: Private health providers in developing countries: serving the public interest? Bennett S, McPake B, Mills A. London: Zed Press; 1997.

75. Ministry of Health. Guidelines for expenditure under health care services fund. Circular Ref. B/13/1/18C/(92), 17 December, 1992. Nairobi: Ministry of Health; 1992.

76. Mintzes B, Hodgkin C. Chapter 5. The consumer movement: from single-issue campaigns to long-term reform. In: Contested ground: Public purpose and private interest in the regulation of prescription drugs. Davis P. Oxford: Oxford University Press; 1996: 76-91.

77. Mooney G. Equity in health care: confronting the confusion. Effective Health Care. 1983; 1: 179-184.

78. Morton-Jones TJ, Pringle MA. Prescribing costs in dispensing practices. BMJ. 1993; 306: 1244-1246.

79. Mossialos E, Ranos C, Abel-Smith B. Cost containment, pricing and financing of pharmaceuticals in the European Community: the policy-makers' view. Athens, Greece: LSE Health and Pharmetrica S A; 1994.

80. MSH. International drug price indicator guide (updated annually). Washington, D C: Management Sciences for Health; 1995.

81. MSH/WHO/DAP. Managing drug supply, 2nd edition. Hartford, CT: Kumarian Press; 1997. Management Sciences for Health in collaboration with World Health Organization, Action Programme on Essential Drugs. Edited by Quick JD, Rankin J, Laing RO, O'Connor R, Hogerzeil HV, Dukes MNG, and Garnet A.

82. Murray CJL, Govindaraj R, Musgrove P. National health expenditures: a global analysis. In: Global comparative assessments in the health sector: Disease burden, expenditures and intervention packages. Murray C, Lopez A. Geneva: World Health Organization; 1994.

83. Murray M. Australian national drug policies: facilitating or fragmenting health? Dev Dialogue. 1995; 1: 148-192.

84. Muschell J. Technical briefing note on privatization in health. Geneva: World Health Organization; 1995. WHO/TFHE/TBN/95.1.

85. Musgrove P. Public and private roles in health: theory and financing patterns. Washington, D C: World Bank; 1996.

86. Mwenesi H, Harpham T, Snow RW. Child malaria treatment practices among mothers in Kenya. Soc. Sci. Med. 1995; 40: 1271-1277.

87. Nolan B, Turbat V. Cost recovery in public health services in Sub-Saharan Africa. EDI Technical Materials. Washington, D C: World Bank; 1995.

88. Normand C, Weber A. Social health insurance: a guidebook for planning. Geneva: World Health Organization; 1994. WHO/SHS/94.3.

89. OECD. Financing and delivering health care: a comparative analysis of OECD countries. Paris: Organization for Economic Cooperation and Development; 1990.

90. OECD. The reform of health care systems: a review of seventeen OECD countries. Paris: Organisation for Economic Cooperation and Development; 1994. Health policy studies, N° 5.

91. OECD. Internal markets in the making: health systems in Canada, Iceland, and the United Kingdom. Paris: Organisation for Economic Cooperation and Development; 1995.

92. Osborne T, Gaebler H. Reinventing government. How the entrepreneurial spirit is transforming the public sector. New York: Addison-Wesley; 1992.

93. Oshiname FO, Brieger W. Primary care training for patent medicine vendord in rural Nigeria. Soc. Sci. Med. 1992; N° 35: 1477-1484.

94. PAHO. Health conditions in the Americas. 1994 edition. Volume 1. Washington, D C: World Health Organization/Pan American Health Organization; 1994. Scientific publication N° 549.

95. Paul S. Capacity-building for health sector reform. Forum on Health Sector Reform discussion paper, N° 5. Geneva: World Health Organization; 1995. WHO/SHS/NHP/95.8.

96. Quick JD. Report of a consultation on ORS supply and distribution in Nigeria. Boston: Management Sciences for Health; 1985.

97. Quick JD, Musau SN. Impact of cost-sharing in Kenya: 1989-1993. Nairobi: Management Sciences for Health; 1994.

98. Reich MR. Political mapping of health policy: a guide for managing the political dimensions of health policy. Boston: DDM Project, Harvard School of Public Health; 1994.

99. Reich MR. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. Health Policy. 1995; 32: 47-77.

100. Robinson R, Le Grand J. Evaluating the NHS reforms. London: King's Fund Institute; 1993.

101. Ron A, Abel-Smith B, Tamburi G. Health insurance in developing countries. A social security approach. Geneva: International Labour Office; 1990.

102. Ross-Degnan D, Soumerai S, Bates J, Goel P, Makhulo J, Sutoto. Improving diarrhoea treatment practices in Kenya and Indonesia. Conference presentation, 31 October-4 November 1993. Yogyakarta: Asian Conference on Clinical Pharmacology and Therapeutics; 1993.

103. Saltman R. Applying planned market logic to developing countries' health systems: an initial exploration. Forum on Health Sector Reform Discussion Paper N° 4. Geneva: World Health Organization; 1995. WHO/SHS/NHP/95.7.

104. Sauerborn R, Ibrango I, Nougtara A, Borchert M, Hien M, Benzler J, et al. The economic costs of illness for rural households in Burkina Faso. Trop. Med. Parasitol. 1995; 46: 54-60.

105. Saxenian H. Getting the most out of pharmaceutical expenditures. Washington, D C: World Bank; 1994.

106. Shaw RP, Griffin CC. Financing health care in sub-Saharan Africa through user fees and insurance. Washington, D C: World Bank; 1995.

107. Sheng-Lan T, Bloom G, Xue-Shan F, Lucas H, Xing-Yuan G, Segall M. Financing health services in China: adapting to economic reform. Brighton: Institute of Development Studies; 1994.

108. Sringernyuang L, Hongvivatana T, Pradabmuk P. Community health workers and drugs: a case study of Thailand. Geneva: World Health Organization; 1994. WHO/DAP/94.19.

109. Stobbelaar F, Chapter 2. (2.1). In: Report of an informal consultation on evolving public-private roles in the pharmaceutical sector, April 1996. Geneva: World Health Organization; 1997: WHO/DAP/97.10.

110. Stobbelaar F. Ensuring value for money from pharmaceuticals. WHO European Health Care Reforms, Lubljana Conference Paper, November 1995. Copenhagen: Deloitte & Touche Management Consultants; 1995.

111. Trap B. Practices by dispensing doctors related to rational drug use and health economics. Presented at: International Conference on Improving Use of Medicines: State of the Art and Future Directions, Chiang Mai: Thailand 1997.

112. Tudor Silva K, Amarasiri de Silva MW, Wijekoon Banda TM. Chapter 12. Access to Western drugs, medical pluralism, and choice of therapy in an urban low income community in Sri Lanka. In: Medicines: meanings and contexts. Etkin NL, Tan ML. Quezon City, Philippines: Health Action Information Network; 1994: 185-208.

113. Van der Geest S, Whyte SR. The context of medicines in developing countries. Studies in pharmaceutical anthropology. Dordrecht/Boston/London: Kluwer Academic Publishers; 1988.

114. Wagstaff A, Van Doorslaer E. Chapter 2. Equity in finance and delivery of health: concepts and definitions. In: Equity in the finance and delivery of health care: an international perspective. Van Doorslaer E, Wagstaff A, Rutten F. Oxford: Oxford University Press; 1993: 7-19.

115. Walsh K. Public services and market mechanisms. Competition, contracting and the new public management. Basingstoke: Macmillan; 1996.

116. Walt G, Gilson L. Reforming the health sector in developing countries: the central role of policy analysis. Health Policy Plan. 1994; 9(4): 353-370.

117. Weerasuriya K. A search for balance: pharmaceuticals in Sri Lanka. Pioneering steps in a receptive environment and subsequent accommodations. Dev Dialogue. 1995; 1: 54-95.

118. WHO. Guidelines for developing national drug policies. Geneva: World Health Organization; 1988.

119. WHO. Review of the drug programme in Indonesia: report of a WHO mission, 16 October-3 November 1989. Geneva: World Health Organization; 1989. DAP/90.11.

120. WHO. The public/private mix in national health systems and the role of ministries of health. Geneva: World Health Organization; 1991. WHO/SHS/NHP/91.2.

121. WHO. Guide for improving diarrhoea treatment practices of pharmacists and licensed drug sellers. Geneva: World Health Organization; 1993. WHO/CDD/93.43.

122. WHO. In: Evaluation of recent changes in the financing of health services: Report of a WHO study group. Geneva: World Health Organization; 1993: 1-74. WHO Technical Report Series, N° 829.

123. WHO. Public/private collaboration for health. National health systems and policies. Geneva: World Health Organization; 1994. WHO/SHS/NDP/94.2.

124. WHO. The developing role of the private health sector in health care and provision of drugs. Geneva: World Health Organization; 1994. DAP/MAC(6)94.8.

125. WHO. Improving complementarity of public/private mix in health and human resources. Report of a consultation, Bangkok, 27 June-1 July 1994. New Delhi: World Health Organization; 1994. SEARO/SEA/HMD/205.

126. WHO. The treatment of malaria: information for non-pharmacists selling antimalarial drugs. Leverkusen: Bayer A. G. 1995.

127. WHO. DAP documents and interviews with WHO staff members. 1995.

128. WHO. Theme paper for discussion: health reform and drug financing: overview of experiences, options and priorities for action. Geneva: World Health Organization; 1997. DAP/MAC(9)97.7.

129. WHO/DAP. Public education in drug use: a growing need. Essential Drugs Monitor. 1994; 18: 1-24.

130. WHO/DAP. Informed therapy. Essential Drugs Monitor. 1995; 19: 1-28.

131. WHO/DAP. Global comparative pharmaceutical expenditures. Health economics and drugs. Geneva: World Health Organization; 1997. (DAP Series N° 3, in preparation).

132. WHO/DAP. Competitive mechanisms for public drug supply: options, issues, and cautions (working draft). Geneva: World Health Organization; 1997.

133. WHO/EURO, Chapter 5. Allocating resources efficiently. In: European health care reforms: Analysis of current strategies. Copenhagen: World Health Organization; 1996: 131-188. EUR/ICP/CARE 94 01/CN01.

134. WHO/SEARO. Privatization of health care: A SEARO kit. New Delhi: WHO Regional Office for South-East Asia; 1995.

135. World Bank. Financing the health sector: an agenda for reform. Washington, D C: World Bank; 1987.

136. World Bank. World development report 1993. Investing in health. New York, NY: Oxford University Press; 1993.

137. World Bank. Better health in Africa. Experience and lessons learned. Washington, D C: World Bank; 1994. Report N° 12577-AFR.

138. World Bank. China: issues and options in health financing. Washington, D C: World Bank; 1996.

139. World Bank. World Development Report 1996. From plan to market. Oxford: Oxford University Press; 1996.

140. Zerda Sarmiento A. Alternativas de políticas de precios de medicamentos in las Americas: Serie “Economía de la Salud y Medicamentos”, N° 1. Geneva: World Health Organization; 1995. WHO/DAP/95.6.